Bleeding and Blood Transfusion in MVR

Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05594420
Collaborator
(none)
40
13

Study Details

Study Description

Brief Summary

To identify the best approach for mitral valve replacement to decrease risk of bleeding and restrict blood transfusion and its complication.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Mitral valve replacement

Detailed Description

Mitral valve disease is the most common form of the valvular heart disorders including mitral regurgitation and mitral stenosis. Surgical treatment includes repair and replacement with different approaches as conventional median sternotomy or minimally invasive approaches.

Since minimally invasive mitral valve surgery (MMVS) was first described in the mid-to-late 1990s by pioneer surgeons Alain Carpentier and Randolph Chitwood, the techniques have evolved to include mini-thoracotomy, port-access thoracoscopic, partial sternotomy, and robotic. Right lateral mini-thoracotomy has become the standard approach for mitral valve surgery in many centers. These approaches may result in less surgical trauma, blood transfusions, and pain, thereby leading to a shorter hospital stay and faster return to daily activities. A reduction in postoperative hemorrhage and transfusion requirements have been suggested as a potential advantage of minimally invasive valve surgery. This benefit is important given the significant morbidity and mortality associated with transfusions and re-exploration for bleeding. Observational studies suggested that patients undergoing MMVS required fewer units of pRBCs transfused per patient and patients were at lower risk of transfusion. RCTs did not reach statistical significance. So, more studies were required to reach a definite conclusion.

Through this study our aim is to evaluate postoperative bleeding and needs for blood transfusion in conventional median sternotomy mitral valve replacement in comparison to minimally invasive approach.

Study Design

Study Type:
Observational
Anticipated Enrollment :
40 participants
Observational Model:
Other
Time Perspective:
Retrospective
Official Title:
Bleeding and Needs for Blood Transfusion in Mitral Valve Replacement, Comparison Between Median Sternotomy and Minimally Invasive Approach.
Anticipated Study Start Date :
Dec 1, 2022
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Jan 1, 2024

Arms and Interventions

Arm Intervention/Treatment
MVR through Median sternotomy

Procedure: Mitral valve replacement
Mitral valve replacement through median sternotomy and minimally invasive approach

MVR through Minimally invasive approach

Procedure: Mitral valve replacement
Mitral valve replacement through median sternotomy and minimally invasive approach

Outcome Measures

Primary Outcome Measures

  1. bleeding [Baseline]

    Amount of post operative bleeding per drains

  2. Blood transfusion [Baseline]

    Amount of blood products transfused

Secondary Outcome Measures

  1. Reexploration [Baseline]

    Number of patients re-explored due to massive bleeding

  2. Complications of blood transfusion [Baseline]

    Complications of blood transfusion

  3. ICU stay [Baseline]

    Numbered of days patient stayed in ICU

  4. Cost effectiveness [Baseline]

    Financial aspect

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients undergoing mitral valve replacement through minimally invasive or median sternotomy at Assiut Cardiothoracic surgery department.
Exclusion Criteria:
  • Patients refused to be enrolled in research. Emergency, redo procedures, active infectious endocarditis, and combined surgery (valve surgery and coronary artery bypass graft).

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Assiut University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Mustafa Loay Mohammed, Resident Doctor, Assiut University
ClinicalTrials.gov Identifier:
NCT05594420
Other Study ID Numbers:
  • Bleeding in MVR
First Posted:
Oct 26, 2022
Last Update Posted:
Oct 26, 2022
Last Verified:
Oct 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 26, 2022